Catalent buys Paragon in hot gene medicine market

By Mike Turner
15 Apr 2019

The US’s Catalent will buy Paragon Bioservices in a debt and equity financed $1.2bn deal, as consolidation in the gene therapy market builds pace.

Catalent makes advanced delivery technologies and development solutions for drugs, biologic products and consumer health products. Paragon is involved in manufacturing products for gene therapy.

Catalent will finance the transaction using a $650m term loan and by issuing $650m of convertible preferred stock to funds linked to private equity firm Leonard Green & Partners, ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.